Drug-Eluting Stents: Clots, Competition and the FDA

There has not yet been any evidence to suggest that the $5 billion worldwide juggernaut, otherwise known as the market for drug-eluting stents, had any risk of imploding over the increased risk of clots following implantation.  However, as we predicted, the occurence of late-stage thrombosis associated with drug-eluting stents is having a de facto impact on this market, even if leaders J&J and Boston Scientific have not ascribed much to either the risk or the prevalence of the problem.

As today’s Wall Street Journal article notes, the very real impact includes depressed sales for both Boston Scientific and J&J, an ostensible increase in attention by new stent manufacturers on the clot problem and an inevitable increase by the the FDA in the length of post-approval studies (up to five years). 

In the October 2006 issue of MedMarkets, we provide a more comprehensive listing of the drug-eluting stents under development (subscribers only), including stents under development by Abbott Vascular, Avantec Vascular, Beijing Lepu Medical Device, Biosensors International, Biotronik, Blue Medical Devices, Boston Scientific, Conor Medsystems, Cordis (J&J), CorNova, Devax, DISA Vascular, Endovasc-TissueGen, Estracure, JW Medical Systems, Medtronic, MicroPort Medical, MIV Therapeutics, OrbusNeich , Relisys Medical Devices, REVA Medical, Sahajanand Medical Technologies, Sorin Biomedica Cardio, Terumo, Translumina, Vascular Concepts, X-Cell Medical and Xtent.

Tags: medtech, stents, drug-eluting

Leave a Reply